Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Plasma levels of alphabeta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease

100%
Sobow T., Flirski M., Kloszewska I., Liberski P. P.
Acta Neurobiologiae Experimentalis
|
2005
|
vol. 65
|
issue 2
117-124
EN
Plasma AlphaBeta levels have been examined in sporadic Alzheimer's disease yielding conflicting results; both no difference and an increase in plasma concentrations of A1-42 and A1-40 in sporadic cases of AD as compared to controls have been reported. Elevated plasma A1-42 levels may be detected several years before the onset of symptoms (in mild cognitive impairment stadium). Levels of AlphaBeta140 and AlphaBeta142 were measured in plasma from 54 patients with AD, 39 subjects with MCI and 35 controls using a commercially available ELISA. Mean plasma AlphaBeta142 levels were significantly higher in MCI as compared to both AD (P<0.001) and control subjects (P<0.001), while AlphaBeta140 did not differ between the groups. No correlations were observed between A levels and age, MMSE scores or gender. According to ROC curve analysis the maximum accuracy in discriminating MCI versus both controls and AD subjects has been achieved using a cut-off value of 3.8.
2
Content available remote

Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease

100%
Sobow T., Flirski M., Liberski P., Kloszewska I.
Acta Neurobiologiae Experimentalis
|
2007
|
vol. 67
|
issue 2
131-139
EN
Cholinesterase inhibitors are currently the mainstream of symptomatic treatment of patients with Alzheimer's disease. The response to treatment with cholinesterase inhibitors is clinically difficult to predict. Several demographic, clinical and biological variables have been proposed as pretreatment predictors of long-term therapy efficacy. In this paper, consistently with previous reports, we confirm that higher initial disease severity and faster progression of cognitive impairment increase the chance of a clinically meaningful response to cholinesterase inhibitor therapy in a carefully selected population of patients with Alzheimer's disease. Moreover, for the first time we demonstrate the association between the increase in the concentration of plasma Abeta(1-42) peptide after 2 weeks of treatment with an initial dose of rivastigmine and the likelihood of a positive response to treatment after 6 months. A change in plasma Abeta(1-42) level might constitute a novel biochemical predictor of rivastigmine treatment efficacy in Alzheimer's disease.
3
Content available remote

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease

100%
Sobow T., Flirski M., Liberski P. P.
Acta Neurobiologiae Experimentalis
|
2004
|
vol. 64
|
issue 1
53-70
EN
With the development of new therapeutic strategies, and the concept of mild cognitive impairment (MCI) as an early stage of Alzheimer's disease (AD), there is an increasing need for an early and accurate diagnosis of sporadic AD. Therefore, biological markers allowing a positive diagnosis early in the course of the disease are highly desirable. The most extensively evaluated markers of sporadic AD are amyloid-beta proteins and levels of both total and phosphorylated microtubule-associated protein tau. In this study, we review the currently available data on the aforementioned markers assessed in the cerebrospinal fluid or plasma, alone and in combinations, focusing on their clinical applicability including sensitivity in the diagnosis of AD and mild cognitive impairment, specificity in discriminating AD from other dementias and correlations with the disease progression and apolipoprotein E genotype. We also analyze advantages and potential drawbacks of using biomarkers in the laboratory diagnosis of AD.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.